{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T10:34:07Z","timestamp":1773916447150,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.ijcard.2015.06.006","type":"journal-article","created":{"date-parts":[[2015,6,15]],"date-time":"2015-06-15T13:06:47Z","timestamp":1434373607000},"page":"133-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint"],"prefix":"10.1016","volume":"196","author":[{"given":"Andrea","family":"Rubboli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Agewall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"Huber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2015.06.006_bb0005","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1093\/eurheartj\/ehu298","volume":"35","author":"Lip","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0010","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1093\/eurheartj\/eht042","article-title":"Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy","volume":"34","author":"Agewall","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0015","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1160\/TH13-09-0803","article-title":"New oral anticoagulant agents \u2014 general features and outcomes in subsets of patients","volume":"111","author":"Schulman","year":"2014","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0020","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0025","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0030","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0035","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1160\/TH14-08-0681","article-title":"The optimal management of patients on oral anticoagulation undergoing coronary artery stenting. The 10th anniversary overview","volume":"112","author":"Rubboli","year":"2014","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0040","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1378\/chest.09-3083","article-title":"\u201cTriple therapy\u201d rather than \u201ctriple threat\u201d: a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment","volume":"139","author":"Zhao","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.ijcard.2015.06.006_bb0045","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/1753944710391925","article-title":"Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation","volume":"5","author":"Singh","year":"2011","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0050","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.cjca.2012.06.012","article-title":"Risk of bleeding on triple antithrombotic therapy after percutaneous coronary intervention\/stenting: a systematic review and meta-analysis","volume":"29","author":"Andrade","year":"2013","journal-title":"Can. J. Cardiol."},{"issue":"Suppl. B","key":"10.1016\/j.ijcard.2015.06.006_bb0055","doi-asserted-by":"crossref","first-page":"80B","DOI":"10.1016\/S0828-282X(07)71016-4","article-title":"Safety of the cardiac triple therapy: the experience of the Quebec Heart Institute","volume":"23","author":"Brulotte","year":"2007","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0060","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s11239-009-0343-1","article-title":"Incidence of hemorrhage among anticoagulated patients receiving antiplatelet therapy after percutaneous coronary intervention","volume":"29","author":"Olson","year":"2010","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.ijcard.2015.06.006_bb0065","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1136\/hrt.2009.167064","article-title":"Therapeutic strategies after coronary stenting in chronically anticoagulated patients: the MUSICA study","volume":"95","author":"Sambola","year":"2009","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2015.06.006_bb0070","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.amjcard.2011.10.046","volume":"109","author":"Nikolsky","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0075","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.amjcard.2012.01.353","article-title":"Antithrombotic management and 1-year outcome of patients on oral anticoagulation undergoing coronary stent implantation (from the Registro Regionale Angioplastiche Emilia-Romagna Registry)","volume":"109","author":"Rubboli","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0080","first-page":"563","article-title":"Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12months in the Warfarin and Coronary Stenting (WAR-STENT) Registry","volume":"26","author":"Rubboli","year":"2014","journal-title":"J. Invasive Cardiol."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0085","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0090","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/eurheartj\/eht049","article-title":"New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis","volume":"34","author":"Oldgren","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0095","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2015.06.006_bb0100","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"ACTIVE Writing Group of the ACTIVE Investigators","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2015.06.006_bb0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0110","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.4244\/EIJV9I11A224","article-title":"Novel oral anticoagulants in acute coronary syndrome: re-evaluating the thrombin hypothesis","volume":"9","author":"Bassand","year":"2014","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ijcard.2015.06.006_bb0115","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ahj.2014.12.006","volume":"169","author":"Gibson","year":"2015","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0120","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1517\/14656566.2013.773310","article-title":"Clinical management of rivaroxaban-treated patients","volume":"14","author":"Palareti","year":"2013","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0125","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5482\/HAMO-13-09-0048","article-title":"Anticoagulation during and after acute coronary syndrome","volume":"34","author":"Ahrens","year":"2014","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.ijcard.2015.06.006_bb0130","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1160\/TH08-11-0730","article-title":"Bleeding with anticoagulation therapy \u2014 who is at risk, and how best to identify such patients","volume":"102","author":"Palareti","year":"2009","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0135","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1161\/CIRCULATIONAHA.113.002332","article-title":"Management and outcomes of major bleeding during treatment with dabigatran or warfarin","volume":"128","author":"Majeed","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2015.06.006_bb0140","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/eurheartj\/ehu463","article-title":"Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial","volume":"36","author":"Held","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0145","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2014-03-563577","article-title":"Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry","volume":"124","author":"Beyer-Westendorf","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ijcard.2015.06.006_bb0150","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1574890109666141205132531","article-title":"Specific antidotes in development for reversal of novel anticoagulants: a review","volume":"9","author":"Gomez-Outes","year":"2014","journal-title":"Recent Pat. Cardiovasc. Drug Discov."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0155","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/eurheartj\/ehs408","article-title":"Acute management of bleeding in patients on novel oral anticoagulants","volume":"34","author":"Siegal","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0160","first-page":"19","article-title":"2012 focused update of the ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0165","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1378\/chest.13-0054","article-title":"Factors affecting quality of oral anticoagulation control among patients with atrial fibrillation on warfarin. The SAMe-TT2R2 score","volume":"144","author":"Apostolakis","year":"2013","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.ijcard.2015.06.006_bb0170","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/europace\/euu353","article-title":"Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists","volume":"17","author":"Abumuaileq","year":"2015","journal-title":"Europace"},{"key":"10.1016\/j.ijcard.2015.06.006_bb0175","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"Windecker","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0180","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1161\/CIRCULATIONAHA.111.055970","article-title":"Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (randomized evaluation of long-term anticoagulation therapy) trial","volume":"125","author":"Hohnloser","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2015.06.006_bb0185","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinternmed.2011.1666","article-title":"Dabigatran association with higher risk of acute coronary events. Meta-analysis of noninferiority randomized controlled trials","volume":"172","author":"Uchino","year":"2012","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0190","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/HCO.0b013e3283021aef","article-title":"Long-term oral anticoagulation in patients with coronary disease, and future developments","volume":"23","author":"Verheugt","year":"2008","journal-title":"Curr. Opin. Cardiol."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0195","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.jacc.2013.03.020","article-title":"Efficacy and safety of dabigatran etexilate and warfarin in \u201creal-world\u201d patients with atrial fibrillation. A prospective nationwide cohort study","volume":"61","author":"Larsen","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0200","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1161\/CIRCULATIONAHA.114.012061","article-title":"Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation","volume":"131","author":"Graham","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2015.06.006_bb0205","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/j.gastro.2013.02.041","article-title":"New oral anticoagulants increase the risk for gastrointestinal bleeding: a systematic review and meta-analysis","volume":"145","author":"Holster","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijcard.2015.06.006_bb0210","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/eurheartj\/ehr342","article-title":"Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment","volume":"32","author":"Fox","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0215","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0225","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1474-4422(12)70258-2","article-title":"Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation","volume":"11","author":"Alberts","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0230","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1056\/NEJMp1103050","article-title":"Anticoagulant options \u2014 why the FDA approved a higher but not a lower dose of dabigatran","volume":"364","author":"Beasley","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0235","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1160\/TH13-12-1032","article-title":"Gaps in translation from trials to practice: non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation","volume":"111","author":"Hylek","year":"2014","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0240","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1160\/TH13-11-0918","article-title":"New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions","volume":"111","author":"Chan","year":"2014","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2015.06.006_bb0245","author":"US National Institutes of Health"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527315013078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527315013078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T20:45:24Z","timestamp":1566852324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527315013078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":48,"alternative-id":["S0167527315013078"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2015.06.006","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2015.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}